Laura Chino-Ríos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laura Chino-Ríos has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Angélica González-Maciel
Instituto Nacional de Pediatría, Mexico City 04530, Mexico
1 shared publication - Beatriz Hernández-Ochoa
Laboratorio de Investigación en Ciencias Ómicas y Epidemiología Microbiana, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City 06720, Mexico
1 shared publication - Diego González-Gómez
Licenciatura en Bioquímica Diagnóstica, Facultad de estudios superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
1 shared publication - Elías Jaime Matadamas-Ortiz
Laboratorio de Investigación de Agro-Recursos y Metabolitos Secundarios, Universidad Autónoma Chapingo, Texcoco 56230, Mexico
1 shared publication - Gabriela López-Herrera
Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, México City 04530, Mexico
1 shared publication - Gloria Hernández-Alcántara
Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, México
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4167
Selective Anti-Giardial Action of Indirubin: Biochemical and Functional Evidence for Inhibition of Triosephosphate Isomerase and Aldose Reductase in Giardia lamblia
The emergence of clinical resistance to conventional antigiardials underscores the need for compounds with novel mechanisms of action. This study demonstrates that indirubin exerts antigiardial activity by targeting important metabolic enzymes in Giardia lamblia. Indirubin induced a concentration-dependent decrease in trophozoite proliferation and viability, correlating with reduced activity of native triosephosphate isomerase and aldose reductase. Using recombinant enzymes, indirubin directly inhibited triosephosphate isomerase and aldose reductase, with the parasite enzymes showing greater susceptibility than their human orthologs. Structural and computational analyses suggest preferential binding of indirubin at the dimer interface of triosephosphate isomerase and within the NADP(H)-binding pocket of aldose reductase. The dual enzymatic inhibition was concordant with methylglyoxal accumulation, extensive protein carbonylation, and the formation of advanced glycation end products. These effects culminated in apoptotic-like death and severe ultrastructural damage, including alteration of the adhesive disc and microtubule networks. By targeting vulnerabilities in the metabolic and redox pathways of G. lamblia through a multifactorial mechanism distinct from current therapies, our findings support indirubin as a promising candidate for the treatment of giardiasis.
- 7 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4167
Open AccessSelective Anti-Giardial Action of Indirubin: Biochemical and Functional Evidence for Inhibition of Triosephosphate Isomerase and Aldose Reductase in Giardia lamblia
The emergence of clinical resistance to conventional antigiardials underscores the need for compounds with novel mechanisms of action. This study demonstrates that indirubin exerts antigiardial activity by targeting important metabolic enzymes in Giardia lamblia. Indirubin induced a concentration-dependent decrease in trophozoite proliferation and viability, correlating with reduced activity of native triosephosphate isomerase and aldose reductase. Using recombinant enzymes, indirubin directly inhibited triosephosphate isomerase and aldose reductase, with the parasite enzymes showing greater susceptibility than their human orthologs. Structural and computational analyses suggest preferential binding of indirubin at the dimer interface of triosephosphate isomerase and within the NADP(H)-binding pocket of aldose reductase. The dual enzymatic inhibition was concordant with methylglyoxal accumulation, extensive protein carbonylation, and the formation of advanced glycation end products. These effects culminated in apoptotic-like death and severe ultrastructural damage, including alteration of the adhesive disc and microtubule networks. By targeting vulnerabilities in the metabolic and redox pathways of G. lamblia through a multifactorial mechanism distinct from current therapies, our findings support indirubin as a promising candidate for the treatment of giardiasis.